Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma
• Age: Between 18 Year(s) - 100 Year(s)
• Gender: Female

• Other Inclusion Criteria:
  

  1. Cancer must have progressed after treatment with all approved and medically appropriate therapies or have no appropriate available therapies. 2. Histologically confirmed diagnosis of one of the following tumor types, along with clinical/pathologic confirmation of the additional requirements for each indication, as appropriate: Persistent or recurrent clear cell carcinoma of the ovary, peritoneum, or endometrium after treatment with platinum-based systemic chemotherapy. Persistent or recurrent high-grade serous carcinoma of the ovary, fallopian tube, or peritoneum after treatment with platinum-based systemic chemotherapy (except subjects with a diagnosis of carcinosarcoma). Recurrent or metastatic cervical carcinoma previously treated with standard-of-care systemic chemotherapy and FDA-approved immunotherapy, if eligible. Advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) in patients who are not candidates for curative surgery or radiation, and that has progressed following treatment with no more than one prior line of systemic therapy and prior treatment with FDA-approved combination therapy. 3. Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
  

You may not be eligible for this study if the following are true:

• 1. Subjects currently receiving other anticancer therapies, except that subjects with prostate cancer may continue to receive luteinizing hormone-releasing hormone (LHRH) analogue therapy. 2. More than 2 prior chemotherapy regimens for subjects in the cervical cancer, CCC, HGSOC, or prostate cancer cohorts. 3. Prior treatment with a CTLA4-targeted agent. 4. Prior treatment with nivolumab, pembrolizumab, or any other PD1-, PDL1- or programmed cell death ligand 2- (PDL2)-directed therapy except for: a. Subjects with MSS EC may have received anti-PD1 therapy as part of an FDA-approved regimen in an approved disease setting. b. Subjects with cervical cancer may have received anti-PD1 therapy as an FDA-approved agent in an approved disease setting. 5. Has any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug. 6. A life-threatening (Grade 4) immune-mediated AE associated with prior administration of an immunotherapy agent.